论文部分内容阅读
诱导多能干细胞(Induced pluripotent stem cells,i PSCs)是利用特定的转录因子诱导体细胞获得的,像胚胎干细胞一样,可以进行无限的自我更新,并具有分化成三个胚层的能力。iPSC有可能提供无限的自体细胞治疗,目前研究已经证实,不同种类疾病的患者提供的成体细胞诱导后可产生种类繁多的iPSC,这项技术给目前无有效治疗手段的多类疾病带来了治疗的希望,并有可能避免利用胚胎干细胞(embryonic stem cells,ESCs)治疗面临的伦理问题和免疫排斥反应。本文回顾iPSC技术优化过程,着重关注应用i PSC建立细胞模型、进行细胞治疗的进展,并探讨iPSC在基础研究及临床应用中遇到的挑战。
Induced pluripotent stem cells (iPSCs) are derived from somatic cells using specific transcription factors. Like embryonic stem cells, iPSCs are capable of indefinite self-renewal and have the ability to differentiate into three germ layers. iPSCs have the potential to provide unlimited autologous cell therapy and current research has demonstrated that a variety of iPSCs can be produced by adult cells provided by patients of different kinds of disease and that this treatment brings a variety of diseases that currently have no effective treatment Hopefully, and possibly avoid the ethical issues and immunological rejection of the treatment of embryonic stem cells (ESCs). This article reviews the iPSC technology optimization process, focusing on the application of i PSC cell model, the progress of cell therapy, and to explore iPSC in basic research and clinical challenges.